Trial Profile

A Pilot Study on the Efficacy of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive by Next Generation Flow

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daratumumab (Primary)
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms DART4MM

Most Recent Events

01 Jun 2026 Primary endpoint has been met. (Overall Responde Rate (ORR))
01 Jun 2026 Results published in the British Journal of Haematology
08 Dec 2020 Results reporting minimal residual disease marrow evaluation at 18 months follow-up presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com